Ads
related to: is simvastatin lifelong treatment- Co-Pay Program
Resources
to Support Your Patients
- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Trial Results
See Clinical Data
and Trial
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Co-Pay Program
Search results
Results From The WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels . [ 4 ]
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
The incidence of rhabdomyolysis was 0.44 per 10,000 patients treated with statins other than cerivastatin. However, the risk was over 10-fold greater if cerivastatin was used, or if the standard statins (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) were combined with a fibrate (fenofibrate or gemfibrozil) treatment ...
So simvastatin is acting in the mouse to block both cholesterol made by the cancer cells themselves and by the liver, and sulfopin is working in the tumor cells to decrease synthesis of cholesterol.
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Treatment for cardiovascular disease depends on which type you have and the severity of your condition. Let’s take a look at the different types of cardiovascular disease and what type of ...